Gliflozins also known as Sodium Glucose Co-Transporter 2 (SGLT2) inhibitors were mainly introduced to treat (T2DM) type 2 diabetes mellitus as an add-on therapy (ADA, 2022; Prosperi et al., 2023; Verdecchia et al., 2023; Yaribeygi et al., 2023). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.